Drugs / [68Ga]Ga-DOTA-H2D3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06715839 | Dec 2024 → Sep 2027 expected | appendix cancer, bile duct carcinoma, esophageal cancer, gallbladder carcinoma +4 | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-H2D3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06715839 ↗ |
| Route | Other | “after \[68Ga\]Ga-DOTA-H2D3 injection” NCT06715839 ↗ |